Recombinant CPA1 抗体 (full length)
Our Local Distributor
北京 101111
Quick Overview for Recombinant CPA1 抗体 (full length) (ABIN7877802)
抗原
See all CPA1 抗体抗体类型
适用
宿主
克隆类型
标记
应用范围
质量等级
克隆位点
-
-
抗原表位
- full length
-
原理
- CPA1 Antibody / Carboxypeptidase A1 (azide and preservative free)
-
纯化方法
- Protein A/G affinity
-
免疫原
- Recombinant full-length human CPA1 protein was used as the immunogen for the CPA1 antibody.
-
亚型
- IgG, kappa
-
-
-
-
应用备注
- Optimal dilution of the CPA1 antibody should be determined by the researcher.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 mg/mL
-
缓冲液
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
储存液
- Azide free
-
储存条件
- -20 °C
-
储存方法
- Aliquot the CPA1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))
-
别名
- CPA1
-
背景
- Human pancreatic procarboxypeptidase A exists as three different active forms, two of which are designated carboxypeptidase A1 (CPA1) and carboxypeptidase A2 (CPA2). CPA1, also known as CPA, is a 419 amino acid secreted monomeric protein that is highly expressed in pancreatic tissue. Functioning as a pancreatic exopeptidase, CPA1 uses zinc as a cofactor to catalyze the release of C-terminal amino acids from a variety of proteins, thereby playing a key role in protein digestion and degradation. Via its catalytic activity, CPA1 is also thought to be involved in zymogen (proenzyme) inhibition, probably functioning to block enzyme activation pathways. Abnormal levels of CPA1 are associated with pancreatic cancer, suggesting a possible role in either tumor progression or tumor suppression events.
-
UniProt
- P15085
抗原
-